Calidi Biotherapeutics (CLDI) AI Stock Analysis

• Market Cap: $15.86M
• Dividend Yield: N/A
• Average Volume (3M): 581.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: N/A
• EPS Growth: 45.23%
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -3.69
• Shares Outstanding: 28,467,580
• 10 Day Avg. Volume: 387,918
• 30 Day Avg. Volume: 581,397
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.50
• Price Target Upside: 331.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

Calidi Biotherapeutics presents a high-risk investment with financial instability and technical weakness. While recent corporate developments offer some optimism, the company's lack of revenue and profitability, combined with bearish technical indicators, weigh heavily on its overall stock score.

Positive Factors

Clinical Trial Results

Early clinical data with a single dose of lead agent CLD-101 showed a near doubling of PFS and OS in some glioma patients.

Regulatory Approval

The FDA has cleared Northwestern University’s IND application for Calidi’s NeuroNova (CLD-101).

Negative Factors

Financial Risk

Given the company's financial situation, even after the offering, there appears to be meaningful risk to the company continuing as a going concern.

Calidi Biotherapeutics Business Overview & Revenue Model

Company Description

Calidi Biotherapeutics (CLDI) is a biotechnology company focusing on the development of innovative oncolytic virus-based therapies for cancer treatments. The company leverages proprietary technology platforms to enhance the therapeutic potential of oncolytic viruses, aiming to improve cancer treatment outcomes. Calidi Biotherapeutics operates within the biopharmaceutical sector, with its primary focus on developing immuno-oncology therapies targeting various cancer types.

How the Company Makes Money

Calidi Biotherapeutics generates revenue through the development and commercialization of its proprietary oncolytic virus-based cancer therapies. The company's revenue streams are primarily derived from partnerships with pharmaceutical companies, licensing agreements, and potential sales of its therapeutic products upon regulatory approval. Calidi collaborates with academic institutions and industry partners to advance its research and clinical trials, which may include milestone payments and royalties from successful commercialization efforts. Additionally, the company may seek funding through grants, equity financing, or strategic alliances to support its research and development activities.

Calidi Biotherapeutics Financial Statement Overview

Summary

Calidi Biotherapeutics faces significant financial challenges with negative revenue growth and profit margins, heavily reliant on external funding. While efforts to reduce liabilities are noted, the financial position remains precarious due to high debt and negative equity, typical for early-stage biotech firms.

Income Statement

Calidi Biotherapeutics has experienced significant financial challenges, with negative revenue growth, gross profit margin, and net income over several years. The company reported no revenue in recent periods, and profit margins remain heavily negative due to high operating costs. This indicates a lack of revenue generation and profitability, typical for early-stage biotechnology firms with high R&D expenses.

Balance Sheet

The balance sheet shows negative equity, indicating that liabilities exceed assets, raising financial stability concerns. High debt levels compared to equity suggest leverage risk, although recent reductions in liabilities indicate some efforts to improve financial health. The negative equity ratio and the high debt-to-equity ratio are significant red flags.

Cash Flow

Cash flow statements show substantial negative free cash flow, with significant outflows in operating activities. This highlights cash burn typical in biotech industries due to high R&D costs. The company has raised capital through financing activities, which is essential for sustaining operations but still indicative of reliance on external funding.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	45.00K	449.00K	0.00
	Gross Profit
-838.00K	-1.26M	-229.00K	355.00K	0.00
	EBIT
-25.29M	-28.99M	-23.13M	-1.78M	-6.77M
	EBITDA
-17.32M	-27.58M	-25.00M	-9.45M	-6.65M
	Net Income Common Stockholders
-17.07M	-29.22M	-25.43M	3.39M	-7.94M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.24M	2.05M	472.00K	1.06M	420.00K
	Total Assets
7.41M	10.02M	2.60M	231.77M	1.85M
	Total Debt
11.71M	7.24M	5.99M	5.18M	11.72M
	Net Debt
10.47M	5.19M	5.52M	4.12M	11.30M
	Total Liabilities
21.98M	18.25M	43.44M	16.45M	24.33M
	Stockholders Equity
-14.57M	-8.23M	-40.84M	215.32M	-22.48M
Cash Flow		Free Cash Flow
-31.90M	-27.57M	-13.64M	-1.29M	-5.18M
	Operating Cash Flow
-31.01M	-26.98M	-13.21M	-1.08M	-4.83M
	Investing Cash Flow
-57.15K	-478.00K	-494.00K	-230.00M	-388.00K
	Financing Cash Flow
31.83M	29.04M	12.09M	232.15M	4.70M

Calidi Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDI, the sentiment is Negative. The current price of 0.58 is below the 20-day moving average (MA) of 0.73, below the 50-day MA of 0.90, and below the 200-day MA of 1.34, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 30.97 is Neutral, neither overbought nor oversold. The STOCH value of 12.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLDI.

Calidi Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
DTIL	48 Neutral	$47.06M	2.48	19.05%	―	40.98%	―
TCRT	47 Neutral	$6.76M	―	-111.83%	―	80.00%	86.70%
ADAP	46 Neutral	$63.99M	―	-273.36%	―	194.23%	45.50%
REPL	40 Neutral	$646.92M	―	-50.50%	―	―	4.28%
CLDI	40 Underperform	$15.86M	―	354.78%	―	―	45.23%

Calidi Biotherapeutics Corporate Events

Calidi Biotherapeutics Reports 2024 Financial Results and Progress

Calidi Biotherapeutics reported its fourth quarter and full-year 2024 financial results, highlighting significant advancements in its clinical programs. The company demonstrated the ability of its CLD-400 platform to deliver gene therapy to tumors and filed an IND for a Phase 1 trial of CLD-201 for solid tumors in March 2025. Recruitment began for a Phase 1 trial of CLD-101 in high-grade glioma patients at Northwestern University, and 14 patients were enrolled in a City of Hope trial for recurrent high-grade glioma. Financially, Calidi reduced its net loss and expenses in 2024 compared to 2023, with increased cash reserves by year-end.

Calidi Biotherapeutics Announces Promising Preclinical Results

On March 10, 2025, Calidi Biotherapeutics announced promising preclinical results for its RTNova platform, which successfully delivered transient gene therapy payloads to tumors. The platform addresses challenges in treating advanced metastatic cancers by using a vaccinia virus strain enveloped with a human cell membrane to target distant tumors. This innovation has shown efficacy in altering the tumor microenvironment and eradicating certain tumors in preclinical models, potentially revolutionizing cancer treatment and opening opportunities for partnerships.

Calidi Biotherapeutics Ends SEPA After Successful Fundraising

On January 28, 2025, Calidi Biotherapeutics announced the termination of its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, effective January 23, 2025. The decision followed a successful fundraising effort that bolstered its cash position to $9.6 million as of December 31, 2024, allowing the company to focus on its clinical and operational goals without the SEPA framework. This strategic move reflects Calidi’s commitment to enhancing shareholder value and advancing its leadership in targeted antitumor virotherapies, with recent progress including an IND clearance by the FDA and new funding from public offerings.

Calidi Biotherapeutics Announces Public Stock Offering Deal

Calidi Biotherapeutics, Inc. has entered into a Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. to sell 5,000,000 shares of its common stock at $0.85 per share in a public offering, expected to close on January 10, 2025. This offering is projected to generate gross proceeds of $4.25 million. The agreement includes restrictions on further stock issuance for a specified period and involves lock-up agreements for company insiders. The Placement Agent will receive an 8% cash fee and a 1% management fee from the proceeds, along with warrants for additional shares. The offering aligns with the company’s strategy to strengthen its financial position within the market.